Amarin Corp Plc (AMRN)

[Ajax133]

James: I was singularly unimpressed by the Jellis study.
Difference in population groups, dose of EPA, and not
particularly elevated Trgs. My own sense is that AMRN
should have used different endpoints with Anchor. To seal
the deal they should have focused on the reduction in
inflammatory markers, as knowledgeable Cardiologists know
that Inflammation is the etiology of Coronary Artery Disease.
BTW, I believe that holds for DM as well. The ACC and AHA
would not have been able to negate that point. An analogy
would be tantamount to a Diabetic presenting with a blood
sugar of 200 and the Doc stating that elevated blood sugar
is the cause of Diabetes. The same with elevated Cholesterol.
I personally believe that inflammation of the intimal lining
(Vasculitis) allows hydrophobic Cholesterol to stick to
the inflammatory site, rather than just being naturally
eliminated. With your stated concern about DM, Statin and
Vascepa works best in that demographic. (low HDL and elevated Trgs.